Lenvatinib, a new oral anti-angiogenic therapy investigated in a study led by researchers at The University of Texas MD Anderson Cancer Center, shows promise for advanced radioiodine-refractory thyroid cancer patients. Patients participating in this Phase III study have shown dramatic improvement in progression-free survival.
No new effective treatment had been available to these patients since the 1940s, but that is changing thanks to this global study led by Steven I. Sherman, M.D., MD Anderson associate vice-provost for Clinical Research, and professor and chair, Endocrine Neoplasia and Hormonal Disorders.
“For decades, in this patient population, the treatment was often to repeat ineffective doses of radio-active iodine, and possibly salvage therapy with chemotherapy,” says Sherman. “About 10 years ago, with the growing availability of novel targeted agents and multi-targeted kinase inhibitors, we began to recognize potential for treating this subgroup of patients with anti-angiogenic therapy and sought to enroll those with refractory disease in clinical trials.”
LEARN more about this new thyroid cancer therapy: http://bit.ly/1J1qB90 #thyroidcancer #hncth #cancerresearch #cancertreatment #thyroidcancertreatment #endcancer